Actively Recruiting
Identification of the Optimal Screening Strategy for Gastric Cancer Prevention
Led by National Taiwan University Hospital · Updated on 2025-08-17
4403
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a prospective, randomized trial to find the best way to screen for H. pylori infection to help prevent gastric cancer. The study compares different screening methods to understand which tests are most acceptable, accurate, and followed well by adults aged 20 years and older who have not previously been screened or treated for H. pylori infection. Participants are randomly placed into groups receiving one of four diagnostic test methods: the carbon-13 urea breath test (UBT), the H. pylori stool antigen test (HpSA), a standard method combining both UBT and HpSA, or a two-stage screening starting with serology followed by confirmation with UBT if positive. Enrollment for the HpSA and two-stage groups has been stopped after initial analysis, and the study continues enrolling participants for the UBT and standard method groups to reach their target numbers. During the study, participants will undergo these screening tests with follow-up assessments over a period from 2 weeks up to 1 year to measure detection rates of H. pylori infection and adherence to the screening. Researchers will monitor compliance and diagnostic accuracy, and assess the potential long-term impact on reducing gastric cancer risk. The study participation duration and testing schedules are designed to collect detailed data on test performance and acceptability.
CONDITIONS
Brief Title
Screening Strategy for Gastric Cancer Prevention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 20 years or older
- Never screened and treated for H. pylori infection
You will not qualify if you...
- Ever undergone gastrectomy
- Patients with gastric cancer
- Have been screened or tested for H. pylori infection
- Ever received H. pylori eradication therapy
- Have taken proton pump inhibitor within two weeks
- Have taken antibiotics within two weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 2 to 8 weeks
Participants undergo diagnostic tests to detect H. pylori infection using different screening methods such as the C13 urea breath test, H. pylori stool antigen test, or a two-stage screening involving serology followed by breath test confirmation.
1 to 2 visits depending on assigned screening method
Duration - 2 weeks to 1 year
Participants' compliance to the screening tests and the long-term outcomes related to gastric cancer risk reduction are observed and assessed.
Periodic visits over up to 1 year
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
J
Jyh-Ming Liou, MD,PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here